📣 VC round data is live. Check it out!

Sysmex Valuation Multiples

Discover Sysmex's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Teleflex, Ypsomed, Getinge, Andon Health and more.

Sysmex Overview

About Sysmex

Sysmex Corp manufactures and sells laboratory testing equipment and reagents. It conducts product development, manufacturing, sales, and service activities in domestic markets, while certain products are also developed, manufactured, and sold through its subsidiaries. The company operates through five reportable segments based on headquarters: Head Office Management, Americas Headquarters, EMEA Headquarters, China Headquarters, and AP Headquarters.


Founded

1968

HQ

Japan

Employees

11.4K

Financials (LTM)

Revenue: $3B
EBITDA: $635M

EV

$5B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sysmex Financials

Sysmex reported last 12-month revenue of $3B and EBITDA of $635M.

In the same LTM period, Sysmex generated $2B in gross profit, $635M in EBITDA, and $229M in net income.

Revenue (LTM)


Sysmex P&L

In the most recent fiscal year, Sysmex reported revenue of $3B and EBITDA of $763M.

Sysmex is profitable as of last fiscal year, with gross margin of 53%, EBITDA margin of 24%, and net margin of 11%.

See analyst estimates for Sysmex
LTMLast FY202320242025202620272028
Revenue$3B$3B$3B$3B$3B
Gross Profit$2B$2B$1B$2B$2B
Gross Margin51%53%53%53%52%
EBITDA$635M$763M$690M$749M$659M
EBITDA Margin20%24%25%24%21%
EBIT Margin11%18%18%18%12%
Net Profit$229M$336M$305M$330M$252M
Net Margin7%11%11%11%8%

Financial data powered by Morningstar, Inc.

Sysmex Stock Performance

Sysmex has current market cap of $6B, and enterprise value of $5B.

Market Cap Evolution


Sysmex's stock price is $9.03.

Sysmex share price increased by 2.9% in the last 30 days, and decreased by 42.9% in the last year.

Sysmex has an EPS (earnings per share) of $0.55.

See more trading valuation data for Sysmex
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5B$6B-1.3%2.9%4.8%-42.9%$0.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sysmex Valuation Multiples

Sysmex trades at 1.7x EV/Revenue multiple, and 8.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Sysmex

EV / Revenue (LTM)


Sysmex Financial Valuation Multiples

As of June 4, 2026, Sysmex has market cap of $6B and EV of $5B.

Sysmex has a P/E ratio of 24.3x.

LTMLast FY202320242025202620272028
EV/Revenue1.7x1.7x1.9x1.8x1.7x
EV/EBITDA8.6x7.2x7.9x7.3x8.3x
EV/EBIT16.1x9.6x11.0x9.9x14.1x
EV/Gross Profit3.4x3.2x3.7x3.3x3.3x
P/E24.3x16.5x18.2x16.8x22.1x
EV/FCF36.0x22.8x51.7x27.1x33.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sysmex Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sysmex Margins & Growth Rates

Sysmex decreased revenue by 1% and EBITDA by 18% in the last fiscal year.

In the most recent fiscal year, Sysmex reported gross margin of 53%, EBITDA margin of 24%, and net margin of 11%.

See estimated margins and future growth rates for Sysmex

Sysmex Margins

Last FY202420252026202720282029
Gross Margin53%53%52%50%
EBITDA Margin24%24%21%20%
EBIT Margin18%18%12%12%
Net Margin11%11%8%7%
FCF Margin8%6%5%6%

Sysmex Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(1%)11%2%4%
Gross Profit Growth(5%)12%(1%)1%
EBITDA Growth(18%)9%(12%)2%
EBIT Growth(43%)11%(30%)(2%)
Net Profit Growth(34%)8%(24%)(2%)
FCF Growth(41%)91%(18%)13%

Data powered by FactSet, Inc. and Morningstar, Inc.

Sysmex Operational KPIs

Sysmex's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Sysmex's Rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sysmex's Rule of X is 31% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sysmex
LTMLast FY202320242025202620272028
Rule of 4026%25%---
Bessemer Rule of X35%31%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.1M---
G&A Expenses to Revenue-30%29%30%30%
R&D Expenses to Revenue6%6%7%6%6%
Opex to Revenue-36%35%35%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sysmex Competitors

Sysmex competitors include Teleflex, Ypsomed, Getinge, Andon Health, Bausch + Lomb, Abbott India, Snibe, Renishaw, Sectra and Novanta.

Most Sysmex public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Teleflex4.0x3.7x13.0x13.1x
Ypsomed6.4x6.4x14.3x14.6x
Getinge1.6x1.6x8.6x8.6x
Andon Health25.2x-12.7x-
Bausch + Lomb2.0x1.9x11.4x10.7x
Abbott India7.7x7.6x24.6x27.7x
Snibe7.2x6.9x16.1x15.7x
Renishaw5.1x4.7x22.8x20.8x

This data is available for Pro users. Sign up to see all Sysmex competitors and their valuation data.

Start Free Trial

Acquisitions by Sysmex

Sysmex has acquired 2 companies to date.

Last acquisition by Sysmex was on December 21st 2023. Sysmex acquired Megakaryon for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Sysmex

Megakaryon
Oxford Gene Technology
Description
Megakaryon Corporation conducts medical research on induced pluripotent stem cell-derived megakaryocytes and platelets for transfusion medicine. The Kyoto, Japan-based firm collaborates on regenerative therapies to address blood shortages.
Oxford Gene Technology supplies genetics research tools including microarrays and next-generation sequencing services to clinical and academic institutions worldwide.
HQ CountryJapanUnited Kingdom
HQ City
Kyoto
Northampton
Deal Date21 Dec 202331 May 2017
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sysmex acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Sysmex

Sysmex has invested in 5 companies to date.

Latest investment by Sysmex was on October 28th 2024. Sysmex invested in Provigate in their $6M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Sysmex

Provigate
VC Cell Therapy
ThinkCyte
IPS Portal
Description
Provigate is a Tokyo-based developer of bio-transistor sensor technologies for health monitoring. The company's wearable devices detect sweat-based biomarkers like lactate and glucose in real time during exercise. Perception-broadening sensors track dynamic physiological changes to support habit formation in fitness and wellness applications. Provigate partners with Japanese sports brands and collaborates on clinical studies for metabolic disorder detection.
VC Cell Therapy is a Tokyo-based company advancing regenerative medicine through research and development. It pioneers AI-powered robots for automated cell production and investigates transplantation of iPS-derived retinal pigment epithelial cells to treat age-related macular degeneration and other retinal diseases. VCCT collaborates with Japanese clinics to enhance patient outcomes in ophthalmology.
ThinkCyte is a Tokyo-headquartered life sciences company specializing in single-cell analysis platforms for research, diagnostics, and cell therapy development. Its proprietary microfluidic and AI-driven Sword Chip technology enables high-throughput isolation and characterization of rare cell populations, supporting applications in oncology and immunology. Backed by investors like Deerfield Management, the firm maintains U.S. operations in South San Francisco.
iPS PORTAL is a Kobe, Japan-based biotechnology service provider specializing in contract testing and quality assurance for induced pluripotent stem (iPS) cells to support research and therapeutic development. The company operates under the Center for iPS Cell Research Application at Kyoto University, offering assays for pluripotency, genetic stability, and differentiation potential. iPS PORTAL facilitates global adoption of iPS technology through standardized testing protocols compliant with Japanese and international regulations, serving academic institutions, pharmaceutical companies, and regenerative medicine firms across Asia and Europe.
HQ CountryJapanJapanJapanJapan
HQ City
Tokyo
Kobe
Tokyo
Kyoto
Deal Date28 Oct 202415 Nov 202319 May 202127 Feb 2015
RoundSeries ASeedSeries BSeries A
Raised$6M$4M$26M$12M
InvestorsAiN Group; Japan Science and Technology Agency; REVIC; SparX Group; Sysmex; Toyoda Gosei CoDai-Dan; Sysmex; YaskawaITOCHU Technology Ventures; SBI Holdings; SparX Group; Sumitomo Mitsui Trust Investment; SysmexAjinomoto; Chugai Pharma; Daiichi Jitsugyo; Daiwa Securities Group; Eisai Co.; Horiba; SCREEN Holdings Co.; Shimadzu; Shin Nippon Biomedical; SMBC Venture Capital; Sumitomo Mitsui Trust Bank; Sysmex
Valuation$39Mundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sysmex investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sysmex

When was Sysmex founded?Sysmex was founded in 1968.
Where is Sysmex headquartered?Sysmex is headquartered in Japan.
How many employees does Sysmex have?As of today, Sysmex has over 11K employees.
Who is the CEO of Sysmex?Sysmex's CEO is Hisashi Ietsugu.
Is Sysmex publicly listed?Yes, Sysmex is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Sysmex?Sysmex trades under 6869 ticker.
When did Sysmex go public?Sysmex went public in 1996.
Who are competitors of Sysmex?Sysmex main competitors include Teleflex, Ypsomed, Getinge, Andon Health, Bausch + Lomb, Abbott India, Snibe, Renishaw, Sectra, Novanta.
What is the current market cap of Sysmex?Sysmex's current market cap is $6B.
What is the current revenue of Sysmex?Sysmex's last 12 months revenue is $3B.
What is the current revenue growth of Sysmex?Sysmex revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Sysmex?Current revenue multiple of Sysmex is 1.7x.
What is the current EBITDA of Sysmex?Sysmex's last 12 months EBITDA is $635M.
What is Sysmex's EBITDA margin?Sysmex's last 12 months EBITDA margin is 20%.
What is the current EV/EBITDA multiple of Sysmex?Current EBITDA multiple of Sysmex is 8.6x.
What is the current FCF of Sysmex?Sysmex's last 12 months FCF is $152M.
What is Sysmex's FCF margin?Sysmex's last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Sysmex?Current FCF multiple of Sysmex is 36.0x.
How many companies Sysmex has acquired to date?As of June 2026, Sysmex has acquired 2 companies.
What was the largest acquisition by Sysmex?None of the M&A deals Sysmex has completed have disclosed valuations.
What companies Sysmex acquired?Sysmex acquired Megakaryon and Oxford Gene Technology.
In how many companies Sysmex has invested to date?As of June 2026, Sysmex has invested in 5 companies.
What was the last Sysmex investment?On 28th October 2024 Sysmex invested in Provigate, participating in a $6M Series A round at $39M valuation, alongside AiN Group, Japan Science and Technology Agency, REVIC, SparX Group, and Toyoda Gosei Co.
In what companies Sysmex invested in?Sysmex invested in RIKEN GENESIS, ThinkCyte, IPS Portal, Provigate, and VC Cell Therapy.

See public comps similar to Sysmex

Lists including Sysmex

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial